LCZ696治疗高血压肾损害的研究进展

摘要/Abstract

摘要： 长期的高血压会导致肾脏功能损害，肾脏功能损害后也会引起高血压，两者互为因果。高血压肾损害的发病是由多种因素共同导致的，例如血管容量负荷增加、肾素-血管紧张素系统异常、氧化应激与炎性反应以及遗传和代谢因素。LCZ696能通过调控肾素-血管紧张素系统，降低容量负荷，显著降低高血压。本文通过详细介绍高血压肾损害的发病机制，以及LCZ696的作用机制及近期研究，综述LCZ696治疗对肾脏病的研究进展。

关键词: LCZ696, 脑啡肽酶抑制剂, 血管紧张素受体抑制剂, 高血压肾损害

Abstract: Chronic hypertension can lead to kidney lesion， and chronic kidney disease can also lead to hypertension， both of which are mutually causal. Hypertensive kidney lesion is caused by a combination of factors， such as increased vascular volume load， renin-angiotensin system abnormalities， oxidative stress and inflammatory responses， genetic and metabolic factors. LCZ696 can control renin-angiotensin system， reduce volume load， significantly reduce hypertension. In this paper， we reviewed the progress of LCZ696 treating renal disease by introducing the pathogenesis of renal damage of hypertension， the action mechanism of LCZ696 and the related recent studies.

Key words: LCZ696, Neprilysin inhibitors, AngiotensinⅡ receptor blockers, Hypertensive kidney lesion

. LCZ696治疗高血压肾损害的研究进展[J]. 中国医药导刊, 2019, 21(9): 560-563.

参考文献

[1] 王力宁，姚丽.高血压性肾损害.中华肾脏病杂志，2005，21(10):569 －571．
[2] Me Murray J，Packer M，Desai A，et a1．A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heat failure[J]. Eur Heat J，2015，36(7)：434—439
[3]Daniel LB,Maisel AS.Natriuretic peptides[J].J Am Coll Cardiol,2007,50:2357-2368.
[4] 李耀中，周海平.新型抗心衰药物 Entresto 的药理作用和临床评价[J].中国新药杂志，2016，25（20）：2313-2318.
[5] 林军华. 利钠肽系统与高血压的研究进展[J]. 医学综述, 2011, 17(17):2585-2587.
[6] E.E. Egom, et al., Evolving use of natriuretic peptide receptor type-C as part of strategies for the treatment of pulmonary hypertension due to left ventricle heart failure, Int J Cardiol (2017), https://doi.org/10.1016/j.ijcard.2018.06.001
[7] ?piranec K,Chen W,Werner F,et al.Endothelial C-Type Natriuretic Peptide Acts on Pericytes to Regulate Microcirculatory Flow and Blood Pressure. Circulation2018;:.DOI:10.1161/CIRCULATIONAHA.117.033383.
[8] Salo PP, Havulinna AS,Tukiainen T,et al.Genome-Wide Association Study Implicates AtrialNatriuretic Peptide Rather Than B-Type Natriuretic Peptide in the Regulation of Blood Pressure in the General Population[J]. Circulation.Cardiovascular genetics ,2017,10(6): 1-32
[9] Y Ogawa, H Itoh, N Tamura, S Suga, T Yoshimasa, M Uehira, S Matsuda, S Shiono, H Nishimoto, and K Nakao.Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene.[J] . The Journal of clinical investigation,1994 , 93 ( 5 ) : 1911 - 1921 .
[10]Meems LMG,Burnett Jc Jr.Innovative Therapeutics: designer natriuretic peptides[J].JACC Bssic Transl Sci,2016,1(7):557-567.
[11]Voors A A, Gori M, Liu L C, et al. Renal effects of the angiotensin receptor neprilysin inhibito LCZ696 in patients with heart failure and preserved ejection fraction [J]. Eur J Heart Fail, 2015, 17(5): 510-517.
[12] Zhang, K, Kaufman, RJ. The unfolded protein response : A stress signaling pathyway critical for health and disease.[J]. Neurology, 2006, 66(2-1): S102-S109
[13] Ferro CJ，Spratt JC，Haynes WG，et al．Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo［J］．Circulation，1998，97( 23) : 2323-2330．
[14]Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–1266.
[15] Fukuda A ，W ickman LT， Venkatareddy MP，et a1．Angiotensin II—dependent persistent podocyte loss from destab ilized glomeruli causes progression of end stage kidney disease[J]．Kidney It，2012，81(1)：40 -55.
[16] 王山. 缬沙坦在高血压治疗中的肾脏保护作用研究[J]. 中外医学研究, 2012, 10(7): 108-111
[17] 郭聪芳, 张畔. 缬沙坦对实验性糖尿病大鼠肾脏的保护作用[J]. 中国中西医结合急救杂志, 2008, 15(3): 185-186.
[18]曹延萍. 内质网应激在糖尿病肾损害过程中的作用及其机制研究[D].河北医科大学,2011.
[19] 刘以鹏，刘淑华，李婷，等．高血压大鼠足细胞的超微病变podocalyxin 的表达及其作用研究．医学研究杂志，2011，40 (11):63 －66
[20] Hoffmann S , Podlich D , Brunhilde Hähnel, et al. Angiotensin II Type 1 Receptor Overexpression in Podocytes Induces Glomerulosclerosis in Transgenic Rats[J]. Journal of the American Society of Nephrology, 2004, 15(6):1475.
[21] Durvasula RV．Shanklan d SJ． Aetivation 0f a local renin angiotensin system in podocytesby glucose[J]．Am J Physiol Renal Physiol，2008，294 (4)：F830一F839
[22] Fukuda A ，W ickman LT， Venkatareddy MP，et a1．Angiotensin II—dependent persistent podocyte loss from destab ilized glomeruli causes progression of end stage kidney disease[J]．Kidney It，2012，81(1)：40 -55.
[23]Judge P,Haynes R,Landray MJ,et al.Neprilysin inhibition in chronic kidney disease [J]. Nephrol Dial Transplant,2015,30:738-743.
[24] von Lueder TG,Atar D,Krum H.Current role of neprilysin inhibitors in hypertension and heart failure,Pharmacol[J].Therapeut,2014,144:41-49.
[25] Benigni A, Zoja C, Zatelli C, et al. Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney Int. 2004;66:1959–1965.
[26] Davis BJ, Johnston CI, Burrell LM, et al. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia. 2003;46:961–971.
[27] Cataliotti A, Boerrigter G, Chen HH, et al. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation. 2002;105:639–644.
[28] Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356:615–620.
[29] Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920–926.
[30] Voors AA, Gori M, Liu LC, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015;17:510–517.
[31] Ito S, Satoh M, Tamaki Y, et al. Safety and efficacy of LCZ696, a firstin-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res. 2015;38:269–275.

快速检索引用检索图表检索高级检索